Xilio Therapeutics, Inc. - Common Stock —— 财务报表 (NASDAQ:XLO) | MetaTrader

展开完整图表完整图表

新闻

Cancer Stocks That Are Advancing the Future of Oncology Care

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Xilio Therapeutics实施1股并14股的反向拆股

Xilio Therapeutics implements 1-for-14 reverse stock split

西利奥治疗公司从权证行权中获得3580万美元

Xilio Therapeutics secures $35.8 million from warrant exercises

Xilio Therapeutics报告从B系列权证行权中获得3580万美元收益

Xilio Development Q3 每股收益逊于预期, 营收超出预期

Xilio Development earnings missed by $0.06, revenue topped estimates